B. Metzler Seel. Sohn & Co. Ag Rocket Pharmaceuticals, Inc. Transaction History
B. Metzler Seel. Sohn & Co. Ag
- $10 Billion
- Q3 2024
A detailed history of B. Metzler Seel. Sohn & Co. Ag transactions in Rocket Pharmaceuticals, Inc. stock. As of the latest transaction made, B. Metzler Seel. Sohn & Co. Ag holds 34,418 shares of RCKT stock, worth $397,872. This represents 0.01% of its overall portfolio holdings.
Number of Shares
34,418
Previous 34,418
-0.0%
Holding current value
$397,872
Previous $741,000
14.3%
% of portfolio
0.01%
Previous 0.01%
Shares
7 transactions
Others Institutions Holding RCKT
# of Institutions
209Shares Held
93.2MCall Options Held
319KPut Options Held
70.3K-
Rtw Investments, LP New York, NY17.7MShares$204 Million5.21% of portfolio
-
Wellington Management Group LLP Boston, MA11.2MShares$130 Million0.04% of portfolio
-
Black Rock Inc. New York, NY6.19MShares$71.6 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.54MShares$64 Million0.0% of portfolio
-
Westfield Capital Management CO LP Boston, MA4.49MShares$51.9 Million0.39% of portfolio
About ROCKET PHARMACEUTICALS, INC.
- Ticker RCKT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 75,683,696
- Market Cap $875M
- Description
- Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a multi-platform biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells...